|Bid||26.07 x 500|
|Ask||35.70 x 100|
|Day's Range||30.51 - 32.32|
|52 Week Range||4.72 - 32.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 30, 2017 - Jun 2, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.90|
UniQure (QURE) spent $64.2 million in operating activities in fiscal 2017 compared to $72.1 million in fiscal 2016. In fiscal 2017, UniQure spent $5.5 million in investing activities compared to $17.1 million in fiscal 2016. In fiscal 2016, UniQure spent $13.4 million on this facility, while in 2017, it spent $3 million.
The major sources of UniQure’s (QURE) revenues are from licensing revenue and collaboration revenue. In fiscal 2017, its license revenue from related parties was $4.1 million compared with $3.9 million in fiscal 2016. A major part of UniQure’s collaboration revenues comes from its collaboration agreement with Bristol-Myers Squibb (BMY) entered into in 2015.
UniQure’s (QURE) adeno-associated virus technology platform and its proprietary insect cell-based manufacturing capabilities provide the company with the potential to reduce development risk, cost, and time to market.
UniQure (QURE) is a leading company in the field of gene therapy. It has a focused pipeline of innovative gene therapies developed both internally and through collaboration for cardiovascular diseases. It has established clinical proof of concept for its lead indication, hemophilia B, and has achieved preclinical proof of concept in Huntington’s disease.
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.
In December 2017, uniQure NV. (NASDAQ:QURE) released its latest earnings announcement, which confirmed that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below,Read More...
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Uniqure NV (NASDAQ: QURE ) shares slid 22 percent in two weeks with no fundamental changes, prompting a Janney analyst to recommend buying the dip. The Analyst Janney analyst Yun Zhong reiterated a Buy ...
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
~On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018. ~Submitted IND Amendment for AMT-061 Dose Confirmation Study, with Topline Data Expected by End of 2018. ~Expects IND Submission ...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2018-- uniQure N.V., a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical, scientific ...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 01, 2018-- uniQure N.V., a leader in human gene therapy, today announced that members of company management or principal investigators will participate ...
Categories: Yahoo FinanceGet free summary analysis uniQure NV reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of uniQure NV – Amgen Inc., bluebird bio, Inc. and BioMarin Pharmaceutical Inc. (AMGN-US, BLUE-US and BMRN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)
On a per-share basis, the Amsterdam-based company said it had a loss of 40 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...